This transmission electron microscope image shows SARS-CoV-2, the virus that causes Covid-19. Credit: NIAID-RML.

Norway-based biopharmaceutical firm BerGenBio has started dosing participants in the Phase II ACCORD clinical trial of bemcentinib to treat hospitalised Covid-19 patients.

Supported by the UK Government, ACCORD is a single clinical trial platform intended to assess drug candidates in early stage trials and advance them into the country’s large-scale Covid-19 studies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bemcentinib is the first candidate selected for assessment as part of the study.

The first patient in the trial has been dosed with bemcentinib at the University Hospital Southampton NHS Foundation Trust. In addition, the trial is open for another seven sites across the UK.

ACCORD clinical academic lead professor Tom Wilkinson said: “The ACCORD platform is allowing us to rapidly test potential new treatments in response to the Covid-19 emergency.

“We believe this programme will be key to developing effective new treatments and are delighted to see the first candidate, bemcentinib, enter the clinic today.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Designed to enrol a total of 120 patients, the study will evaluate the safety and efficacy of bemcentinib as an add‑on therapy to standard of care (SoC). Of the total participants, 60 will receive the drug, while the remaining 60 will be given SoC.

BerGenBio expects top-line results from the trial in the coming months. In case of positive data, the drug will advance into the large-scale Phase III trials in the UK.

BerGenBio CEO Richard Godfrey said: “We are delighted that dosing has commenced with bemcentinib in the ground-breaking ACCORD study and we hope that patients will swiftly start to see benefits.

“Initiating this clinical trial in such short order is the result of tremendous teamwork between my colleagues at BerGenBio and the teams at IQVIA and UHS, among many others.”

The company is also studying bemcentinib in a Phase II oncology clinical development programme.